Operating expenses also increased by a little more than $1 million in Q1 of 2011 compared to Q1 of 2010 due to investments toward a planned human clinical trial of its biopolymer scaffolding device for spinal cord injuries. Part of the increased operating expenses was also due to incurred costs associated with public company practices, according to the news release.
Read the company news release about InVivo Therapeutics’ financial results (pdf).
Related Articles on Device Company Financial Results:
SANUWAVE Posts Q1 $252K Revenue, 76% Increase
TranS1 Reports $5.1M in Q1 Revenues, 24% Decrease
DJO Global Reports $249.7M in Q1 Net Sales
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
